ArticleSpine2026
Opioid and Neuropathic Pain Medication Use After ACDF for Degenerative Cervical Spine Disease-Nationwide FinSpine Register Study.
Article in Spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designLongitudinal, nationwide register study.
objectiveTo examine the use of opioids and neuropathic pain medications after primary anterior cervical discectomy and fusion (ACDF) for degenerative cervical spine disease (DCSD), and to identify independent factors associated with postoperative use. SUMMARY OF BACKGROUND DATA: ACDF is used for cervical radiculopathy and myelopathy, yet many patients continue analgesic use postoperatively. Prolonged opioid use is associated with dependence, poorer clinical outcomes, and reduced return-to-work rates. Evidence on postoperative medication trajectories and their predictors in population-based cohorts remains limited. MATERIALS AND
methodsData were obtained from the nationwide FinSpine register and the Finnish prescription database, which records all outpatient prescription drug purchases. Consecutive patients undergoing primary ACDF for DCSD between 2017 and 2022 were included. Repeated purchases were defined as at least two purchases of the same drug during months 2 to 12 postoperatively. New strong-opioid users were defined as patients who were strong-opioid naïve six months preceding surgery and met the repeated postoperative purchase criterion. Multivariable logistic regression was used to identify independently associated covariates.
resultsThe cohort included 4366 patients. Preoperatively, 41.9% (n=1830) purchased opioids and 41.2% (n=1798) gabapentinoids. Repeated postoperative purchases were observed in 16.5% for opioids and 15.6% for gabapentinoids. Among preoperative opioid and gabapentinoid users, cessation rates were 69.5% and 70.9%, respectively. In previously strong-opioid naïve patients, the incidence of new repeated strong-opioid purchases was 2.2% after ACDF. Independent predictors of repeated postoperative purchases included preoperative pain duration of more than one year, smoking, higher baseline NDI, central canal stenosis, adverse working status, and preoperative purchases of the same drug class.
conclusionA considerable proportion of patients continued to purchase opioids and gabapentinoids during the first postoperative year after ACDF. New strong-opioid initiation postoperatively was uncommon. Nationwide prescription data offer an objective and complete measure of postoperative medication dispensing for outcome assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.